John J. Mastrototaro is Vice President, Research, Technology & Business Development/Chief Technology Officer at Medtronic Diabetes since November 2011. In this role, John oversees research and development of all drug delivery products including activities focused on development of the artificial pancreas. In addition, John is leading efforts to expand global R&D activities to address specific needs in local geographies. Previously, he served as the Vice President of Global Clinical, Scientific & Health Affairs, where he was responsible for global clinical research, clinical outcomes management, closed-loop and algorithm development initiatives, and health policy programs.
John first joined MiniMed in 1993 to initiate a continuous glucose monitoring (CGM) project. He has held a variety of leadership positions within the R&D team and led the effort to develop and commercialize the world’s first ambulatory CGM system which was launched in 1999..
John is an internationally renowned expert in diabetes technology and has authored dozens of publications in peer reviewed journals on original technical and clinical research and consensus reports. In 2003, John received the Bakken Award from Medtronic Inc. for his scientific & research contributions in the field of diabetes.
Prior to joining Medtronic, John was a technical project manager for Eli Lilly and Company focusing on the development of electroenzymatic and non-invasive glucose monitoring systems.
John received his Masters and PhD degrees in Biomedical Engineering from Duke University in Durham, North Carolina. John holds 51 US patents.